Novavax | NVAX - Operating Expenses


Novavax reported $218.53M in Operating Expenses for its fiscal quarter ending in September of 2024.





Operating Expenses Change Date
Adma Biologics USD 83.21M 4.02M Sep/2025
Agenus USD -274.14M 80.46M Sep/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Cassava Sciences USD 11.86M 2.23M Sep/2025
Geron USD 58.8M 2.31M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
MannKind USD 119.64M 56.29M Dec/2025
Merck USD 10.16B 558M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Moderna USD 1.54B 259M Dec/2025
Novartis USD 9.77B 401M Sep/2025
Novavax USD 218.53M 34.86M Sep/2024
Pfizer USD 12.91B 79.89B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
TG Therapeutics USD 142.08M 9.74M Dec/2025